duotrav and dorzolamide-timolol-combination

duotrav has been researched along with dorzolamide-timolol-combination* in 2 studies

Reviews

1 review(s) available for duotrav and dorzolamide-timolol-combination

ArticleYear
[The latest developments in glaucoma therapy using fixed combination products].
    Oftalmologia (Bucharest, Romania : 1990), 2011, Volume: 55, Issue:3

    Modern fixed-combination products simplify medication dose regimen without sacrificing their effectiveness.Potential benefits of the therapy with fixed-combination products are enhanced tolerability increased convenience,better compliance,cost and time economy and removal of the wash out effect. Regarding intraocular pressure lowering effect, fixed-combination agents are superior to monotherapy with the two medication components, with the exception of Duotrav that is not superior to travoprost action.Fixed-combination products are noninferior to concomitant administration of the two components of medication (nonfixed-combination agents) relative to their ocular hypotensive efficacy with the exception of Ganfort that is however inferior to concurrent administration of both the bimatoprost and timolol.

    Topics: Amides; Antihypertensive Agents; Bimatoprost; Brimonidine Tartrate, Timolol Maleate Drug Combination; Carbonic Anhydrase Inhibitors; Cloprostenol; Drug Combinations; Drug Therapy, Combination; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiazines; Thiophenes; Timolol; Travoprost; Treatment Outcome

2011

Other Studies

1 other study(ies) available for duotrav and dorzolamide-timolol-combination

ArticleYear
The transcorneal penetration of commercial ophthalmic formulations containing timolol maleate in rabbit eyes.
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2015, Volume: 31, Issue:1

    We investigated the transcorneal penetration of commercial ophthalmic formulations containing timolol maleate in rabbit eyes.. One drop (30 μL) of each ophthalmic solution (Xalacom(®), DuoTrav(®), Cosopt(®), and Timoptol(®)) was administered to the conjunctival sac of the rabbits' eyes and the timolol maleate aqueous humor concentration was measured by high-performance liquid chromatography 15, 60, 120, and 240 min after the completion of administration. The effect of timolol ophthalmic solution pH (5.7-6.8) on ocular penetration was also examined.. The concentration [Cmax (μg/mL)] of timolol maleate, found in each of the 4 ophthalmic solutions, penetrated to the aqueous humor was as follows: DuoTrav>Cosopt>Timoptol>Xalacom. The concentration of timolol maleate penetrated to the aqueous humor was highest with solutions in the vicinity of pH 6.8.. The concentration of timolol maleate penetrated to the aqueous humor was highest in DuoTrav followed by Cosopt, Timoptol, and Xalacom, and the pH and Benzalkonium chloride (BAK) concentration of the ophthalmic solution were believed to be factors that influenced this phenomena.

    Topics: Animals; Benzalkonium Compounds; Chromatography, Liquid; Cloprostenol; Cornea; Drug Combinations; Eye; Glaucoma; Male; Ophthalmic Solutions; Preservatives, Pharmaceutical; Prostaglandins F, Synthetic; Rabbits; Sulfonamides; Thiophenes; Timolol

2015